Trial
NCT00981903
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Southern California
Collaborators
Celgene Corporation
Condition
Venous Thromboembolism
Intervention
Tinzaparin sodium
Why stopped
Tinzaparin will no longer be available in the United States
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-07-06